Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a Form 8-K signed September 19, 2023, reporting events occurring primarily on September 14 and September 18, 2023. The filing concerns financing arrangements, board changes, and Nasdaq listing compliance. It does not provide quarterly financial statements or operating results.
Key Financial and Capitalization Matters
- The maturity date of the company’s Pre-Paid Advance Agreement with YA II PN, Ltd. (Yorkville) was extended from September 15, 2023, to December 31, 2023.
- Yorkville agreed not to declare an event of default under the agreement until January 1, 2024.
- Celularity agreed to pay down $2.5 million of the outstanding prepaid advance: $2.0 million by October 5, 2023, and $0.5 million by October 31, 2023.
- If a subsequent financing results in unrestricted cash and cash equivalents of at least $8.0 million, the company must make a payment to Yorkville from financing proceeds exceeding that threshold while the advance remains outstanding.
- As consideration for the maturity extension, Celularity issued Yorkville 2,707,308 shares of Class A common stock with piggyback registration rights. The shares were issued in an unregistered transaction under Section 4(a)(2) and Regulation D.
- The filing does not provide the outstanding balance of the prepaid advance, the company’s cash balance, revenue, profit, cash flow, margins, or debt totals.
Material Changes Versus the Prior Comparable Period
- The financing maturity was extended by approximately three and a half months, with temporary protection against an event of default.
- The company incurred a required $2.5 million partial repayment obligation and issued additional equity to Yorkville, resulting in dilution to existing shareholders.
- Lim Kok Thay resigned immediately from the board and all committees. The board reduced its size from nine to seven members, eliminating vacancies associated with his departure and the previously reported departure of John Sculley.
- Nasdaq granted an additional 180-day period, through March 11, 2024, for Celularity to regain compliance with the $1.00 minimum bid-price requirement.
Guidance, Outlook, Risks, and Unusual Items
- The company stated that it intends to cure the Nasdaq bid-price deficiency during the additional compliance period, potentially through a reverse stock split.
- Compliance may be achieved if the closing bid price reaches at least $1.00 for 10 consecutive business days. If a reverse stock split is used, it must be completed no later than 10 business days before March 11, 2024.
- Failure to regain compliance could result in Nasdaq delisting proceedings.
- The Yorkville arrangement indicates near-term liquidity and refinancing risk, including required cash repayments and a potential use of future financing proceeds.
- The 2,707,308 shares were not registered for resale at issuance and carry piggyback registration rights. The filing states that the definitive agreement was intended to be filed later as an exhibit to the company’s Form 10-Q for the quarter ended September 30, 2023.
- The filing states that Mr. Lim’s resignation was not due to disagreement with the company’s operations, policies, or practices.
Important Facts for Investors to Verify
- Verify the outstanding Yorkville prepaid-advance balance, repayment status, and whether the October 2023 payment obligations were satisfied.
- Review the definitive letter agreement and subsequent Form 10-Q for all financing terms, default provisions, and registration rights.
- Assess the dilution from the 2,707,308 issued shares and any additional equity financing.
- Confirm whether Celularity regained Nasdaq’s minimum bid-price compliance by March 11, 2024 and whether a reverse stock split occurred.
- Review subsequent filings for liquidity, cash balances, financing proceeds, and any Nasdaq delisting notices.